BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Eli Lilly Accused of Keeping the Over 40 Crowd Out of Sales Rep Roles

  Lilly’s most recent legal woes come from a proposed class-action lawsuit filed on Wednesday, accusing the company of age bias.

  September 3, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Policy

  COVID-19: Supply Chain, Antibodies and Autoimmune Impacts

  Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.

  September 3, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  U.S. Officials Rush to Reassure as Mu Variant Grabs International Headlines

  The Mu variation is the fifth strain to be designated as a “variant of interest” by the World Health Organization.

  September 3, 2021

   · 

  3 min read

   · 

  BioSpace Editorial Staff
• 

  Deals

  Scopus Biopharma Flexes Immuno-Oncology Pipeline Following Its Acquisition of Olimmune

  Scopus Biopharma recently launched Duet Therapeutics to integrate its immunotherapy assets’ management and clinical development with Olimmune.

  September 3, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Disappointment for Forte Biosciences After Lead Asset Fails in Atopic Dermatitis

  Shares of Forte Biosciences plunged more than 80% in premarket trading after the company announced failure to demonstrate statistical significance of Phase II atopic dermatitis trial.

  September 3, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Novartis Scuttles Kidney Transplant Drug Study

  Novartis announced that it is discontinuing the trial in kidney transplant patients after conducting an interim analysis from its CIRRUS-1 trial of CFZ533 (iscalimab).

  September 3, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  BioCapital

  Clinical Catch-Up: August 30-September 3

  There were a fair number of clinical trial announcements last week. Here’s a look.

  September 3, 2021

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  FDA Action Alert: Impel and Merck

  Sometimes the U.S. Food and Drug Administration (FDA) runs ahead of schedule. In the case of this week’s two PDUFA dates, that was completely true. Here’s a look.

  September 3, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Pharm Country

  Celsion DNA Vaccine Platform Produces Potent Response in Preclinical Study

  Celsion announced results from its PLACCINE DNA vaccine platform that showed it produced antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2.

  September 3, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Tech Companies Are Breeding Grounds for Some Big Data Life Science Company Executives

  With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.

  September 3, 2021

   · 

  3 min read

   · 

  Alex Keown